BIOREGENX, INC.

BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies through its subsidiaries. The company was originally incorporated on December 23, 1998, in Nevada as Findit, Inc. Effective March 8, 2024, BioRegenx, Inc., a Nevada corporation, merged into Findit, Inc., resulting in a change of control and the company's name changing to BioRegenx, Inc. As part of the merger, all outstanding BioRegenx, Inc. common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series A preferred shares of the Company, representing 90.0% of its voting securities. Concurrently, holders of the Company's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares, which represented 98.47% of the Company's voting control. Simultaneously, majority shareholders retired a total of 172,197,602 common shares. The Company also effected a 16 for 1 split of its common shares. The Company and its subsidiaries are conducting clinical studies for certain products. The Company's products and operations are subject to regulation by the U.S. Food and Drug Administration and other federal and state authorities.